Christian Mueller

Christian Mueller

Auto-generated profile, based on publicly available information

Christian Mueller

Genomic Medicine Unit, Sanofi, Waltham, Massachusetts, USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 October 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
KMKatharina E. Meijboom
Katharina E. Meijboom
AAAbbas Abdallah
Abbas Abdallah
NFNicholas P. Fordham
Nicholas P. Fordham
HNHiroko Nagase
Hiroko Nagase
TRTomas Rodriguez
Tomas Rodriguez
CMChristian Mueller
Christian Mueller
A GGGGCC24+ hexanucleotide repeat expansion (HRE) in the C9ORF72 gene is the most common genetic cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), fatal neurodegenerative diseases with no cure or approved treatments that substantially slow disease progression or extend survival. Mechanistic underpinnings of neuronal death include C9ORF72 haploinsufficiency, sequestration of RNA-binding proteins in the nucleus, and production of dipeptide repeat proteins. Here, we used an adeno-associated viral vector system to deliver CRISPR/Cas9 gene-editing machineries to effectuate the removal of the HRE from the C9ORF72 genomic locus. We demonstrate successful excision of the HRE in primary cortical neurons and brains of three mouse models containing the expansion (500–600 repeats) as well as in patient-derived iPSC motor neurons and brain organoids (450 repeats). This resulted in a reduction of RNA foci, poly-dipeptides and haploinsufficiency, major hallmarks of C9-ALS/FTD, making this a promising therapeutic approach to these diseases.

8 March 2022 in JCI Insight
Verified
Journal Article
Open access
PDF file
NHNan He
Nan He
XLXiaoming Liu
Xiaoming Liu
AVAmber R. Vegter
Amber R. Vegter
TET. Idil A. Evans
T. Idil A. Evans
JGJaimie S. Gray
Jaimie S. Gray
BRBradley H. Rosen
Bradley H. Rosen
Alpha-1 antitrypsin deficiency (AATD) is the most common genetic cause and risk factor for chronic obstructive pulmonary disease, but the field lacks a large-animal model that allows for longitudinal assessment of pulmonary function. We hypothesized that ferrets would model human AATD-related lung and hepatic disease. AAT-knockout (AAT-KO) and PiZZ (E342K, the most common mutation in humans) ferrets were generated and compared with matched controls using custom-designed flexiVent modules to perform pulmonary function tests, quantitative computed tomography (QCT), bronchoalveolar lavage (BAL) proteomics, and alveolar morphometry. Complete loss of AAT (AAT-KO) led to increased pulmonary compliance and expiratory airflow limitation, consistent with obstructive lung disease. QCT and morphometry confirmed emphysema and airspace enlargement, respectively. Pathway analysis of BAL proteomics data revealed inflammatory lung disease and impaired cellular migration. The PiZ mutation resulted in altered AAT protein folding in the liver, hepatic injury, and reduced plasma concentrations of AAT, and PiZZ ferrets developed obstructive lung disease. In summary, AAT-KO and PiZZ ferrets model the progressive obstructive pulmonary disease seen in AAT-deficient patients and may serve as a platform for preclinical testing of therapeutics including gene therapy.

15 February 2013 in Current Protocols in Microbiology
Verified
Journal Article
Open access
PDF file
AGAlisha M. Gruntman
Alisha M. Gruntman
LBLawrence T. Bish
Lawrence T. Bish
CMChristian Mueller
Christian Mueller
HSH. Lee Sweeney
H. Lee Sweeney
TFTerence R Flotte
Terence R Flotte
GGGuangping Gao
Guangping Gao
Adeno‐associated virus (AAV) is a DNA virus with a small (∼4.7 kb) single‐stranded genome. It is a naturally replication‐defective parvovirus of the dependovirus group. Recombinant AAV (rAAV), for use as a gene transfer vector, is created by replacing the viral rep and cap genes with the transgene of interest along with promoter and polyadenylation sequences. Only the viral inverted terminal repeats (ITRs) are required in cis for replication and packaging during production. The ITRs are also necessary and sufficient for vector genome processing and persistence during transduction. The tissue tropism of the rAAV vector is determined by the AAV capsid. In this unit we will discuss several methods to deliver rAAV in order to transduce cardiac and/or skeletal muscle, including intravenous delivery, intramuscular delivery, isolated limb infusion, intrapericardial injection in neonatal mice, and left ventricular wall injection in adult rats. Curr. Protoc. Microbiol. 28:14D.3.1‐14D.3.19. © 2013 by John Wiley & Sons, Inc.

21 December 2021 in mBio
Verified
Journal Article
Open access
MMMario Meza-Segura
Mario Meza-Segura
JBJames R. Birtley
James R. Birtley
AMAna Maldonado-Contreras
Ana Maldonado-Contreras
CMChristian Mueller
Christian Mueller
KSKarl J. Simin
Karl J. Simin
BMBeth A. McCormick
Beth A. McCormick
Shigellais the second leading cause of diarrheal death globally. In this study, we identified the host protein targets of SepA,Shigella’s major protein secreted in culture.

26 September 2023 in Gene Therapy
Verified
Journal Article
Closed access
PDF file
GCGabriela Toro Cabrera
Gabriela Toro Cabrera
KMKatharina E. Meijboom
Katharina E. Meijboom
AAAbbas Abdallah
Abbas Abdallah
HTHelene Tran
Helene Tran
ZFZachariah Foster
Zachariah Foster
CMChristian Mueller
Christian Mueller

13 April 2022 in Molecular Therapy - Methods & Clinical Development
Verified
Journal Article
Open access
MZMarina Zieger
Marina Zieger
FBFlorie Borel
Florie Borel
CGCynthia Greer
Cynthia Greer
GGGwladys Gernoux
Gwladys Gernoux
MBMeghan Blackwood
Meghan Blackwood
CMChristian Mueller
Christian Mueller
α1-antitrypsin deficiency is a rare genetic condition that can cause liver and/or lung disease. There is currently no cure for this disorder, although repeated infusions of plasma-purified protein may slow down emphysema progression. Gene therapy in which a single recombinant adeno-associated viral vector (rAAV) administration would lead to sustained protein expression could therefore similarly affect disease progression, and provide the added benefits of reducing treatment burden and thereby improving the patient’s quality of life. The study presented here tests whether treating the Serpina1a-e knockout mouse model of α1-antitrypsin-deficiency lung disease with gene therapy would have an impact on the disease course, either on spontaneous disease caused by aging or on accelerated disease caused by exposure to cigarette smoke. Liver-directed gene therapy led to dose-dependent levels of biologically active human α1-antitrypsin protein. Furthermore, decreased lung compliance and increased elastic recoil indicate that treated mice had largely preserved lung tissue elasticity and alveolar wall integrity compared with untreated mice. rAAV-mediated gene augmentation is therefore able to compensate for the loss of function and restore a beneficial lung protease-antiprotease balance. This work constitutes a preclinical study report of a disease-modifying treatment in the Serpina1a-e knockout mouse model using a liver-specific rAAV serotype 8 capsid.